Financial Report: Lilly

Lilly
4Q Revenues: $6.2 billion (+7%)
4Q Loss: $1.7 billion (earnings were $771.8 million 4Q16)
FY Revenues: $22.9 billion (+8%)
FY Loss: $204.1 million (earnings were $2.7 billion FY16)
Comments: Newer products contributed to growth in the quarter. Trulicity sales were $649.0 million, up 93%. Cyramza sales were $204.8 million, up 16%. Basaglar sales were $153.8 million, up 289%. Taltz sales were $172.5 million, up 182%. Jardiance sales were $143.2 million, up 88%. Growth in the quarter was offset by Strattera (down 60% to $98.3 million) and Effient (down 56% to $62.3 million) due to loss of exclusivity. Humalog sales were $782.2 million in the quarter, down 5% due to lower pricing. Cialis sales were $597.4 million, down 12% as a result of decreased demand. Forteo sales were up 21% in the quarter to $513.2 million. Humulin sales were $362.6 million, up 2%. Results in the quarter include an estimated charge of $1.9 billion associated with recently enacted U.S. tax reform legislation and charges associated with the company’s restructuring.